Elyan Partners-advised ERES IV takes majority stake in Oncodesign Services

• ERES IV bought 61.58% of the company and the will file a simplified tender offer on the remaining shares 
• Elyan Partners is the exclusive adviser to the ERES funds
• The share price has been increased to €14.42 per share from the initial estimate of €14.41

Elyan Partners announced the completion of the acquisition of a majority stake in Oncodesign Services via the ERES IV fund. The purchase was 61.58% of the firm’s share capital from the company’s main shareholders, including founder Philippe Genne.

Dijon, France-based Oncodesign Services is a contract research organisation specialising in drug discovery and preclinical services in oncology and immuno-inflammation.

Elyan Partners will file a simplified tender offer for the remaining shares. The price was increased to €14.42 per share from the initial estimate of €14.41, following the audit of the Oncodesign balance sheet as of 31 May.

Paris-headquartered Elyan Partners is a member of the Edmond de Rothschild Private Equity partnership and is the exclusive adviser to the ERES funds.

“We are delighted to have reached this important milestone and confirm our intention to support the management team of Oncodesign Services in the pursuit of organic growth, possibly combined with acquisitions aimed at increasing the company’s scientific expertise, access to other customers or other geographies,” said Jean-François Félix, Vincent Manès and Maxence de Vienne, partners at Elyan.